If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.35    0.00 (0.00%)
Bid:
6.30
Ask:
6.40
Spread: 0.10 (1.587%)
Market Cap: £6.56m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Half Yearly Results

18 Jul 2014 07:00

RNS Number : 6690M
Ducat Ventures PLC
18 July 2014
 



Ducat Ventures Plc ("Company")

 

Half Yearly Report

 

The Board of Ducat presents the unaudited historical financial information of the Company for the 6 months to 31 May 2014. 

 

Consolidated Statement of Comprehensive Income

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

 to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

Continuing operations

 

 

£

£

 

 

 

 

 

Revenue

 

 

-

-

Cost of Sales

 

 

-

-

 

 

 

───────

───────

 

 

 

 

 

Gross Loss

 

 

-

-

 

 

 

 

 

Administrative expenses

 

 

(57,643)

(166,453)

 

 

 

───────

───────

Operating Loss

 

 

(57,643)

(166,453)

 

 

 

 

 

Non Operating Items

 

 

 

 

Impairment of investments

 

 

-

(500,000)

Impairment of intercompany loans

 

 

-

(1,384,068)

Surplus arising on settlements with trade creditors

 

 

 

-

 

-

 

 

 

───────

───────

 

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Finance Costs

 

 

-

-

 

 

 

───────

───────

Loss Before Tax

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Taxation

 

 

-

-

 

 

 

───────

───────

Total comprehensive income for the period

 

 

 

(57,643)

 

(2,050,521)

 

 

 

═══════

═══════

 

 

 

 

 

Loss per share

 

 

0.006p

2.29p

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

Consolidated Balance Sheet

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

ASSETS

 

 

£

£

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

Trade and other receivables

 

 

10,034

49,077

Cash and cash equivalents

 

 

105,221

4,945

 

 

 

───────

───────

 

 

 

115,255

54,022

 

 

 

───────

───────

 

 

 

 

 

Total Assets

 

 

115,255

54,022

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

Shareholders' Equity

 

 

 

 

Called up share capital

 

 

5,742,586

5,636,083

Share premium

 

 

1,355,502

1,086,875

Share based payment reserve

 

 

27,200

27,200

Retained earnings

 

 

(7,013,950)

(6,830,754)

 

 

 

───────

───────

Total Equity

 

 

111,338

(80,596)

 

 

 

───────

───────

 

 

 

 

 

LIABILITIES

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

Trade and other payables

 

 

3,917

134,618

 

 

 

───────

───────

 

 

 

3,917

134,618

 

 

 

───────

───────

Total Equity and Liabilities

 

 

115,255

54,022

 

 

 

══════

═══════

 

 

 

Consolidated statement of changes in equity

For the six months ended May 2014

 

 

 

 

Called up

Share

Capital

 

 

Share

Premium

Share-

Based

Payment

Reserve

 

 

Retained

Earnings

 

 

Total

Equity

 

£

£

£

£

£

 

 

 

 

 

 

Balance at 1 August 2012

5,574,070

838,822

27,200

(4,780,233)

1,659,859

 

 

 

 

 

 

Loss for period

-

-

-

(2,050,521)

(2,050,521)

 

 

 

 

 

 

Issue of shares

62,013

248,053

-

-

310,066

 

───────

──────

──────

───────

───────

Balance at 31 May 2013

5,636,083

1,086,875

27,200

(6,830,754)

(80,596)

 

 

 

 

 

 

Loss for the period

-

-

-

(125,553)

(125,553)

 

 

 

 

 

 

Issue of shares

86,165

215,936

-

-

302,101

 

───────

──────

──────

───────

───────

Balance at 30 November 2013

5,722,248

1,302,811

27,200

(6,956,307)

95,952

 

 

 

 

 

 

Loss for the period

-

-

-

(57,643)

(57,643)

 

 

 

 

 

 

Issue of ordinary shares at £0.0004 per shares less cost

 

20,338

 

52,691

-

 

 

-

 

73,029

 

───────

──────

──────

───────

───────

Balance at 31 May 2014

5,742,586

1,355,502

27,200

(7,013,950)

113,338

 

══════

══════

══════

══════

═══════

 

 

Consolidated Statement of Cash Flows

As at 31 May 2014

 

 

 

 

 

Six months

 to 31 May

2014

Six months 

to 31 May

2013

 

 

(Unaudited)

(Unaudited)

 

 

£

£

 

 

 

 

Cash flows from operating activities

 

 

 

Loss before tax

 

(57,643)

(166,453)

(Increase)/decrease in trade and other

 receivables

 

 

291,233

 

(81,262)

Increase)/decrease in trade and other

payables

 

 

(201,548)

 

(57,416)

 

 

───────

───────

Net cash from operating activities

 

32,042

(305,131)

 

 

───────

───────

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

Issue of equity net of costs

 

73,029

310,067

Finance interest paid

 

-

-

 

 

───────

───────

Net cash from financing activities

 

73,029

310,067

 

 

───────

───────

 

 

 

 

Increase/(decrease) in cash and cash

equivalents

 

 

105,071

 

4,936

 

 

 

 

Cash and cash equivalents at the beginning of period

 

 

150

 

9

 

 

───────

───────

Cash and cash equivalents at the end of period

 

 

105,221

 

4,945

 

 

══════

═══════

 

 

 

 

 

Enquiries:

 

For further information, please contact:

Ducat Ventures plc

Nicholas Nelson

07921 522 920

Cairn Financial Advisers LLP

Liam Murray / Avi Robinson

020 7148 7900

Peterhouse Corporate Finance Ltd

Lucy Williams/ Duncan Vasey

020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FMGMNVNFGDZM
Date   Source Headline
6th Aug 20187:00 amRNSProposed directorate change
31st Jul 201810:04 amRNSDirector's dealing
17th Jul 20187:00 amRNSGrant of Options
12th Jul 20187:00 amRNSDirector's dealing
6th Jul 201812:00 pmRNSHolding(s) in Company
4th Jul 20182:07 pmRNSResult of AGM
4th Jul 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSAgreement with global corporate for SweetBiotix®
21st Jun 20187:00 amRNSExclusive license agreement for LPLDL®
18th Jun 20187:00 amRNSManufacturing agreement with Morley Foods
14th Jun 20187:00 amRNSExercise of Options and Issue of Equity
11th Jun 20187:00 amRNSNotice of AGM
7th Jun 20187:00 amRNSUS launch of LPLDL® with Seed Health
31st May 20187:00 amRNSSweetBiotix® agreement with global dairy company
30th May 20187:00 amRNSPlacing and Issue of Equity
23rd May 20187:00 amRNSFinal Results
22nd May 20187:00 amRNSLP-LDL agreement for USA
18th May 20187:00 amRNSSlimBiome® wins award at Vitafoods 2018
16th May 20184:40 pmRNSHolding(s) in Company
16th May 20187:00 amRNSExclusive manufacturing and supply agreement
8th May 20187:00 amRNSLaunch of extended range of products at Vitafoods
1st May 20187:00 amRNSLP-LDL? news media interest in USA
30th Apr 20187:00 amRNSNotice of Results
24th Apr 20187:00 amRNSSlimBiome non-exclusive UK distribution agreement
19th Apr 20187:00 amRNSAppointment of Head of Online Sales and Marketing
18th Apr 20187:00 amRNSCholBiome exclusive distribution agreement
5th Apr 20187:00 amRNSNew patent filings for SweetBiotix
27th Mar 20187:00 amRNSScientific and commerical update
8th Mar 20187:00 amRNSLaunch of Slimbiome in Nutri-bites
6th Mar 20187:00 amRNSLPLDL® Exclusive European License Agreement
28th Feb 20187:00 amRNSOptiBiotix Capital Reorganisation
6th Feb 20187:00 amRNSExercise of warrant and issue of equity
1st Feb 20182:22 pmRNSDirector's dealing
30th Jan 20183:03 pmRNSExercise of warrant and issue of equity
25th Jan 201811:45 amRNSResult of Meeting
23rd Jan 20187:00 amRNSSweetBiotix® development: human taste studies
17th Jan 20187:00 amRNSPresentation of data at European Conference
8th Jan 20183:12 pmRNSShareholder Circular and Notice of General Meeting
8th Jan 20187:00 amRNSDirectorate Changes
14th Dec 20173:35 pmRNSExercise of warrant and issue of equity
12th Dec 20177:00 amRNSManufacturing, supply & profit sharing agreement
5th Dec 20177:00 amRNSProposed directorate changes
28th Nov 20177:00 amRNSCapital reorganisation
17th Nov 20173:06 pmRNSExercise of Warrant and Issue of Equity
8th Nov 20177:00 amRNSSlimBiome® commercial & product development update
1st Nov 20177:00 amRNSManufacturing, supply & profit sharing agreement
26th Oct 20177:00 amRNSPresentation of research
24th Oct 20177:00 amRNSLPLDL® supply agreement with Galenicum
4th Oct 20177:00 amRNSSuccessful launch of products at Supply Side West
19th Sep 20177:00 amRNSTechnical, regulatory & commercial update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.